Increasing Prevalence of Eczema Correlates with Severity of Alopecia Areata

Higher severity of alopecia areata is linked to increased prevalence and risk of eczema, underscoring the importance of monitoring for atopic dermatitis in affected patients.
Recent research published in the Journal of Investigative Dermatology highlights a significant association between the severity of alopecia areata (AA) and the prevalence and incidence of atopic dermatitis (AD), commonly known as eczema. The study, led by Dr. Christopher G. Bunick and team from Yale School of Medicine, analyzed data from the Merative MarketScan Research Databases involving patients aged 12 and older diagnosed with AA. The findings indicate that patients with more severe forms of AA tend to have higher rates of AD. Specifically, the prevalence of AD among AA patients was found to be 3.2% at baseline, with a notably higher prevalence of 7.6% among adolescents. Furthermore, the risk of developing AD increased with the severity of AA—those with moderate to severe AA had a 78% higher chance of being diagnosed with eczema than those with mild AA. These patterns persisted across all age groups, and patients diagnosed by dermatologists also showed higher rates of comorbid AD. The authors suggest that routine monitoring for eczema in patients with severe AA could facilitate earlier interventions, potentially improving patient outcomes. Several authors disclosed ties to biopharmaceutical companies, including funding from AbbVie. Overall, the study emphasizes the need for heightened awareness of dermatologic comorbidities in patients suffering from alopecia areata, particularly those with severe disease manifestations.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Majority of Women Report Positive Experiences with NHS Maternity Services, New Study Finds
Recent research shows that the majority of women have positive experiences with NHS maternity services, highlighting improvements in antenatal and labor care, despite ongoing challenges such as communication and staffing issues.
Innovative, Cost-Effective Biosensor Pill Detects Intestinal Inflammation via Blue Dye Release
A new low-cost, ingestible biosensor pill from researchers at Mass General Brigham and the University of Toronto offers a simple, non-invasive way to detect intestinal inflammation by releasing a visible blue dye, promising better at-home monitoring for IBD patients.
Artificial Intelligence Enhances Identification of Candidates for Targeted Breast Cancer Therapies
AI technology is transforming breast cancer diagnosis by improving the accuracy of HER2 testing, potentially expanding targeted therapy options for more patients. A new study demonstrates how AI assists pathologists in better identifying low and ultralow HER2 levels, opening avenues for personalized treatment. source: https://medicalxpress.com/news/2025-05-ai-id-candidates-breast-cancer.html
China Launches Nationwide Genomic Framework to Improve Rare Disease Diagnosis
A large-scale genomics study in China has established a new diagnostic framework for rare diseases, significantly improving detection rates and paving the way for better patient outcomes worldwide.



